Basel, Switzerland – [Current Date] – Novartis’s ambitious foray into rare disease therapeutics has hit a significant roadblock, as its Avidity Biosciences-acquired therapy, delpacibart etedesiran (del-desiran), failed to meet its primary endpoint in a pivotal Phase III study for myotonic dystrophy type 1 (DM1). This late-stage clinical setback not only casts a shadow over the substantial $12 billion acquisition of Avidity Biosciences but also adds pressure to Novartis’s pipeline at a critical juncture, with several blockbuster drugs facing impending patent expirations.
n
Main Facts: A Major Clinical Disappointment
n
The disheartening news emerged from the HARBOR study (NCT06411288), a comprehensive Phase III trial designed to evaluate the efficacy and safety of del-desiran, an innovative antibody-oligonucleotide conjugate (AOC), against a placebo. The study enrolled 150 patients suffering from myotonic dystrophy type 1 (DM1), a debilitating genetic muscle-wasting disorder, with treatment administered intravenously over a 54-week period.
n
The primary objective of the HARBOR trial was to demonstrate a statistically significant improvement in patient video hand opening times (vHOT) compared to the placebo group. vHOT is a clinically validated and sensitive measure that assesses the delay in a patient’s ability to relax their hand muscles after a forceful squeeze, a characteristic symptom of myotonia in DM1. Unfortunately, del-desiran did not achieve this crucial endpoint, signaling a significant clinical failure for the investigational therapy.
n
This failure reverberates beyond the immediate clinical outcome. Analysts had previously highlighted the HARBOR study’s success as a critical determinant in justifying the hefty $12 billion price tag Novartis paid for Avidity Biosciences in 2025. The inability of del-desiran to deliver on its primary efficacy endpoint raises serious questions about the return on investment for this major acquisition and its broader implications for Novartis’s strategic growth objectives.
n
While the primary endpoint was missed, Novartis has indicated that del-desiran did exhibit "some signs of clinical activity" across both secondary endpoints and exploratory analyses. However, specific details regarding these observations remain undisclosed. According to the trial listing on ClinicalTrials.gov, secondary endpoints for HARBOR included assessments of hand grip strength, a patient’s ability to walk or run, overall muscle strength, and daily functional capabilities. The lack of clear primary endpoint success, despite any potential secondary signals, poses a significant challenge for the program’s future.
n
Chronology: The Road to HARBOR and Analyst Expectations
n
The journey of del-desiran into Novartis’s portfolio began with the colossal $12 billion acquisition of Avidity Biosciences in 2025. This strategic move was heralded by Novartis as a means to bolster its pipeline with groundbreaking RNA-based therapeutics, particularly targeting rare diseases with high unmet medical needs. Avidity Biosciences was at the forefront of developing antibody-oligonucleotide conjugates (AOCs), a novel class of precision medicines designed to deliver oligonucleotide therapies directly to specific cell types and tissues. The promise of this platform was immense, offering a potential solution to overcome the delivery challenges inherent in RNA therapeutics.
n
At the time of the acquisition, del-desiran, along with delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD) and delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD), formed the core assets acquired by Novartis. Del-desiran, in particular, was viewed as a flagship candidate due to its advanced clinical stage and the profound unmet need in the DM1 patient community. The rationale was clear: by acquiring Avidity, Novartis aimed to rapidly expand its footprint in genetic disorders and leverage a cutting-edge technological platform.
n
As the HARBOR trial progressed and its readout approached, financial analysts closely monitored its developments. In a research note issued in July 2026, analysts from Jefferies explicitly stated that the HARBOR trial "needed to deliver" to justify the substantial $12 billion investment in Avidity. Their assessment underscored the critical importance of del-desiran’s success not just for the immediate valuation of the acquisition, but also for Novartis’s longer-term financial projections. The analysts further cautioned that a failure in this late-stage trial could significantly impede Novartis’s ability to achieve its ambitious mid-single-digit growth target leading up to 2030, potentially necessitating further large-scale mergers and acquisitions to fill the gap. This prognosis now appears to be an uncomfortable reality for the Swiss pharmaceutical giant.
n
Supporting Data: Clinical Details, Disease Burden, and Therapeutic Promise
n
The HARBOR study’s design reflects the complexity of assessing efficacy in a multifaceted disorder like DM1. Myotonic dystrophy type 1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 9.27 in every 100,000 individuals, particularly among populations of European ancestry. It is a progressive, inherited neuromuscular disorder caused by an unstable CTG trinucleotide repeat expansion in the DMPK gene. This genetic anomaly leads to the production of toxic RNA, which in turn sequesters RNA-binding proteins, disrupting normal cellular function and protein synthesis. The result is a wide spectrum of symptoms, including progressive muscle wasting and weakness, myotonia (delayed muscle relaxation), cataracts, cardiac conduction abnormalities, respiratory insufficiency, endocrine dysfunction, and cognitive impairment.
n
Currently, the treatment landscape for DM1 is largely confined to symptomatic and supportive care. There are no approved disease-modifying therapies that can halt or reverse the progression of the disease. This stark reality underscores the immense unmet medical need and explains why a therapeutic candidate like del-desiran was met with such high anticipation from both clinicians and patient advocacy groups. The prospect of a drug directly addressing the underlying genetic pathology of DM1 represented a paradigm shift in treatment.
n
Del-desiran, as an antibody-oligonucleotide conjugate (AOC), was designed to specifically target the toxic RNA transcripts in DM1. The AOC platform essentially combines the precision targeting capabilities of an antibody, which can deliver the therapeutic payload to specific cell types (in this case, muscle cells), with the gene-modulating power of an oligonucleotide. This innovative approach aimed to reduce the levels of toxic DMPK RNA, thereby restoring normal cellular function and alleviating disease symptoms. The selection of vHOT as the primary endpoint was based on its direct relevance to myotonia, one of the most debilitating and characteristic symptoms experienced by DM1 patients, and its ability to objectively quantify muscle relaxation time.
n
The failure to improve vHOT significantly, despite the potential signals in secondary and exploratory analyses, presents a difficult challenge. While secondary endpoints can offer insights into other aspects of a drug’s activity, regulatory approvals typically hinge on the successful achievement of a well-defined primary endpoint. The lack of specific details from Novartis regarding the positive signals in secondary analyses makes it challenging to ascertain their clinical meaningfulness or potential to sway future development decisions. This ambiguity leaves the DM1 patient community, who had placed considerable hope in del-desiran, without a clear path forward for this specific therapy.
n
Official Responses: Navigating Uncertainty
n
In the wake of the HARBOR study results, Novartis’s Chief Medical Officer, Shreeram Aradhye, acknowledged the outcome, stating that the company will "continue to explore the full HARBOR dataset" to determine the next steps for the del-desiran program. This statement, while offering a glimmer of hope for potential hidden insights within the extensive data, also reflects the company’s predicament.
n
"Exploring the full dataset" typically involves conducting detailed subgroup analyses, scrutinizing the performance of secondary and exploratory endpoints with greater statistical rigor, and attempting to identify patient populations that might have responded more favorably. It is a standard practice following a primary endpoint miss, aimed at salvaging any potential therapeutic signal or understanding why the trial did not succeed as anticipated.
n
However, the path forward for del-desiran appears fraught with challenges. Even if compelling signals emerge from secondary analyses, securing regulatory approval without a clear primary endpoint success is exceptionally difficult, particularly for a disease where robust efficacy data is paramount. Regulators often require unequivocal evidence of clinical benefit on a predefined primary measure. Novartis will face a critical decision: whether to invest further resources in additional trials, potentially with modified endpoints or patient populations, or to discontinue the del-desiran program altogether. Given the significant investment already made through the Avidity acquisition and the pressing need for pipeline successes, this decision will undoubtedly be subject to intense internal scrutiny and external pressure.
n
For the DM1 patient community, Novartis’s statement offers a degree of uncertainty rather than immediate relief. The absence of an approved disease-modifying therapy means that the wait for an effective treatment continues, and the failure of a promising candidate like del-desiran is a significant disappointment.
n
Implications: Broader Impact on Novartis and the Industry
n
The HARBOR study’s failure is more than just a single clinical trial miss; it has profound implications for Novartis’s overall strategic direction, financial health, and pipeline resilience.
n
Impact on Novartis’s Pipeline Ambitions: This setback is not an isolated incident for Novartis. It follows closely on the heels of another high-profile Phase III failure earlier this year, involving its lipoprotein(a) [Lp(a)]-reducing drug, pelacarsen, in the closely watched Lp(a)HORIZON trial for cardiovascular disease. These consecutive late-stage blunders create a challenging narrative for Novartis, which has been actively pursuing pipeline diversification and innovation to secure its long-term growth. The failures in both cardiovascular and rare disease spaces underscore the inherent risks in drug development, even for highly anticipated assets.
n
While these setbacks are significant, it is important to contextualize them within Novartis’s broader R&D efforts. The company recently announced resounding late-stage success for its Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, in relapsing multiple sclerosis (RMS). This positive development offers a much-needed silver lining and demonstrates that Novartis’s pipeline is not entirely devoid of promising candidates. However, the balance between successes and failures will be crucial as the company navigates a period of intense pressure.
n
Justifying the Avidity Acquisition and Future M&A Strategy: The $12 billion acquisition of Avidity Biosciences was a bold move, intended to provide a significant boost to Novartis’s rare disease portfolio and innovative technology platforms. The failure of del-desiran, the most advanced asset from that acquisition, makes justifying such a substantial investment considerably more difficult. It raises questions about the due diligence process and the valuation placed on Avidity’s pipeline. The market will undoubtedly be watching closely for any potential write-downs related to the acquisition’s goodwill. This situation could also influence Novartis’s future M&A strategy, potentially making the company more cautious in pursuing large-scale deals, especially those centered on early-stage or unproven technologies, or it might force them into further M&A to meet growth targets.
n
The Looming Patent Cliff: Adding to Novartis’s strategic challenges is the impending "patent cliff" for several of its blockbuster drugs. Key revenue drivers such as the heart failure therapy Entresto (sacubitril/valsartan) and the autoimmune drug Cosentyx (secukinumab) are nearing the end of their market exclusivity periods. The loss of patent protection will expose these drugs to generic competition, inevitably leading to a significant decline in sales. This makes successful pipeline replenishment and the launch of new, high-value products absolutely critical for Novartis to maintain its revenue base and achieve its ambitious growth targets. The recent pipeline failures exacerbate the pressure to find and develop new blockbusters quickly.
n
Implications for AOC Technology and Rare Disease Development: While del-desiran’s failure is a blow, it does not necessarily invalidate the entire antibody-oligonucleotide conjugate (AOC) platform or the broader approach to rare disease drug development. AOCs represent a promising frontier in precision medicine, offering targeted delivery of genetic therapies. The failure could be specific to del-desiran’s design, its target in DM1, or the clinical trial’s endpoints, rather than a fundamental flaw in the AOC technology itself. Other Avidity assets, such as del-zota for DMD and del-brax for FSHD, are still in earlier stages of development and might yet prove the value of the platform. However, investors and the industry will undoubtedly scrutinize future AOC clinical data with heightened caution.
n
For the rare disease community, the HARBOR trial’s outcome is a stark reminder of the challenges inherent in developing treatments for complex, often poorly understood genetic conditions. Despite significant scientific advancements, translating cutting-edge research into effective therapies remains a formidable task. The continued unmet need in DM1 underscores the urgent requirement for ongoing research and development efforts, even in the face of setbacks.
n
In conclusion, the failure of del-desiran in the HARBOR study marks a significant setback for Novartis, impacting its pipeline, acquisition strategy, and overall financial outlook. While the company navigates this challenge and assesses the detailed data, the broader pharmaceutical industry will be closely observing how Novartis recalibrates its strategy to overcome these hurdles and deliver on its long-term growth ambitions amidst a rapidly evolving and competitive landscape. The promise of innovative therapies for rare diseases remains, but the path to delivery is proving to be as challenging as ever.
n
